Streetbeat News

BWAY

BrainsWay Ltd.

https://www.brainsway.com

Industry

Medical - Devices

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Wall Street analysts have updated their price targets and ratings for several US-listed companies, leading to varied stock price movements. Notable adjustments include increases in price targets for RingCentral, Robinhood Markets, Emerson Electric, Arm Holdings, The Cheesecake Factory, BrainsWay, Uber Technologies, Amgen, and The Trade Desk, with a decrease for Cardlytics.

Portfolio Pulse from Avi Kapoor

May 09, 2024 | 12:28 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on BrainsWay (NASDAQ:BWAY) and increased the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:17 am

BrainsWay has reaffirmed its FY24 revenue guidance, projecting revenues between $37M-$40M, indicating a 16% to 26% growth over its FY23 revenue. The company also expects to maintain its profitability momentum and positive cash generation throughout 2024.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:52 am

BrainsWay (NASDAQ:BWAY) reported Q1 sales of $9.095M, surpassing the analyst consensus estimate of $8.720M by 4.30%, marking a 37.28% increase from the previous year's sales of $6.625M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:34 am

BrainsWay Ltd. (NASDAQ: BWAY) announced results from a review article published in Frontiers of Human Neuroscience, highlighting the potential of Deep Transcranial Magnetic Stimulation (Deep TMS) to treat Parkinson's Disease (PD). The review, which summarized data from six studies involving 220 patients, showed clinically meaningful improvements in motor and non-motor symptoms. The company emphasized the need for further research, noting that Deep TMS is not yet FDA cleared for treating PD.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:12 pm

BrainsWay announced the publication of post-marketing analysis results on late-life depression in the Journal of Clinical Medicine. The study likely showcases the effectiveness of BrainsWay's technology in treating this condition, which could influence the company's reputation and potentially its financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:10 pm

BrainsWay's existing partner, Katie's Way Plus, has expanded its order by adding 18 more Deep Transcranial Magnetic Stimulation (Deep TMS) systems, increasing their total to around 40 systems. This expansion indicates a growing demand for Deep TMS technology and a strengthening partnership between BrainsWay and Katie's Way Plus.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:33 am

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on BrainsWay (NASDAQ:BWAY) and increased the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:27 am

BrainsWay reported its Q4 earnings per ADS at $0.00, surpassing the estimated $(0.01). This indicates a positive performance against market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:44 pm

BrainsWay has projected its full-year 2024 revenue to be between $37M and $40M, surpassing the estimated $35.7M. The company also expects to maintain its profitability momentum and continue generating cash.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.